Veoza Approved for Use on the NHS
Veoza (fezolinetant) has been officially approved for use on the National Health Service (NHS) in England, marking a significant advancement in the treatment of menopausal hot flushes. This new oral medication is expected to benefit approximately 500,000 women who experience these symptoms, which affect around 70% of women undergoing menopause.
Targeting Hot Flushes
The approval of Veoza is particularly noteworthy as it offers an alternative for women for whom hormone replacement therapy (HRT) is unsuitable. Hot flushes and night sweats can severely impact the quality of life, and Helen Knight from the National Institute for Health and Care Excellence (NICE) emphasized the importance of this treatment, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.”
How Veoza Works
Veoza operates by blocking nerve pathways in the brain that trigger hot flushes and night sweats, providing a once-daily oral tablet option for women. The NHS list price for Veoza is set at £44.80 per 28-tablet pack, and NICE has determined that fezolinetant is cost-effective, offering value for taxpayers.
Expert Opinions
Experts in women’s health have welcomed the approval, with Dr. Sue Mann noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” This sentiment reflects a growing recognition of the need for diverse treatment options in managing menopausal symptoms.
For decades, there have been few safe and effective treatment options for menopausal hot flushes, leaving many women to cope with uncomfortable symptoms without adequate relief. The introduction of Veoza represents a pivotal moment in addressing this long-standing gap in women’s health care.
Future Implications
With the approval of Veoza, healthcare professionals anticipate that it will provide much-needed relief to those suffering from menopausal symptoms. Helen Knight remarked, “This decision will give much-needed relief to those for whom HRT is unsuitable,” highlighting the importance of expanding treatment options for women.
What Lies Ahead
As Veoza becomes available, observers will be monitoring its uptake and effectiveness among the target population. The potential impact on the lives of hundreds of thousands of women could be significant, allowing them to better manage their symptoms and regain control over their health. Details remain unconfirmed regarding the long-term effects and broader implications of this treatment.